Orion and Glykos in research collaboration and licensing agreement on next-generation ADCs

 Under the agreement, Orion gains access to Glykos’ proprietary ADC technologies, initiating an ADC program with the potential for expansion into two additional programs in the future. Orion will be responsible for the target selection, research, development, and commercialization of up to three next-generation ADCs, with a focus on solid tumors.

Glykos is eligible for milestone payments related to signing of the agreement, target selection and sales milestones. Glykos is also entitled to receive royalties on commercial sales generated from the three ADC programs.

https://www.biospace.com/article/releases/orion-and-glykos-announce-research-collaboration-and-licensing-agreement-to-develop-next-generation-adcs/